CN102861034B - Gypensapogenin A在治疗或预防急性心衰的药物中的应用 - Google Patents
Gypensapogenin A在治疗或预防急性心衰的药物中的应用 Download PDFInfo
- Publication number
- CN102861034B CN102861034B CN201210418058.9A CN201210418058A CN102861034B CN 102861034 B CN102861034 B CN 102861034B CN 201210418058 A CN201210418058 A CN 201210418058A CN 102861034 B CN102861034 B CN 102861034B
- Authority
- CN
- China
- Prior art keywords
- gypensapogenin
- heart failure
- acute heart
- medicine
- treating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- PYGRZYXAMLFMOS-IBMFSSKUSA-N gypensapogenin a Chemical compound O=C1C(=C(C)C)CC=C1[C@@H]1[C@@H](CC[C@H]2[C@]3(CCC4=C2[C@H]2CC[C@H](O2)C4(C)C)C)[C@@]3(C)CC1 PYGRZYXAMLFMOS-IBMFSSKUSA-N 0.000 title claims abstract description 56
- 206010007556 Cardiac failure acute Diseases 0.000 title claims abstract description 19
- 239000003814 drug Substances 0.000 title claims abstract description 12
- 238000011282 treatment Methods 0.000 claims abstract description 12
- 238000002360 preparation method Methods 0.000 claims description 8
- 238000011321 prophylaxis Methods 0.000 claims description 4
- 150000001875 compounds Chemical class 0.000 abstract description 11
- 230000000694 effects Effects 0.000 abstract description 3
- 206010019280 Heart failures Diseases 0.000 description 10
- 241000282472 Canis lupus familiaris Species 0.000 description 7
- 230000000747 cardiac effect Effects 0.000 description 6
- 241000282465 Canis Species 0.000 description 3
- 240000006509 Gynostemma pentaphyllum Species 0.000 description 3
- 235000002956 Gynostemma pentaphyllum Nutrition 0.000 description 3
- QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 3
- 229960002275 pentobarbital sodium Drugs 0.000 description 3
- 229930182490 saponin Natural products 0.000 description 3
- 150000007949 saponins Chemical class 0.000 description 3
- 235000017709 saponins Nutrition 0.000 description 3
- 150000003648 triterpenes Chemical class 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 210000000709 aorta Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- INLFWQCRAJUDCR-IQVMEADQSA-N (1R,2S,4S,5'S,6R,7S,8R,9S,12S,13S)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-oxane] Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CCCCC4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@H](C)CO1 INLFWQCRAJUDCR-IQVMEADQSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010020850 Hyperthyroidism Diseases 0.000 description 1
- 235000003143 Panax notoginseng Nutrition 0.000 description 1
- 241000180649 Panax notoginseng Species 0.000 description 1
- 208000006193 Pulmonary infarction Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 230000035606 childbirth Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- OORMXZNMRWBSTK-UHFFFAOYSA-N dammaran Natural products C1CCC(C)(C)C2CCC3(C)C4(C)CCC(C(C)CCCC(C)C)C4CCC3C21C OORMXZNMRWBSTK-UHFFFAOYSA-N 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 210000001198 duodenum Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003191 femoral vein Anatomy 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 230000000004 hemodynamic effect Effects 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000005240 left ventricle Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000005622 photoelectricity Effects 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000007575 pulmonary infarction Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000012109 statistical procedure Methods 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000002627 tracheal intubation Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Landscapes
- Steroid Compounds (AREA)
Abstract
Description
Claims (1)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210418058.9A CN102861034B (zh) | 2012-10-26 | 2012-10-26 | Gypensapogenin A在治疗或预防急性心衰的药物中的应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210418058.9A CN102861034B (zh) | 2012-10-26 | 2012-10-26 | Gypensapogenin A在治疗或预防急性心衰的药物中的应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN102861034A CN102861034A (zh) | 2013-01-09 |
CN102861034B true CN102861034B (zh) | 2014-04-16 |
Family
ID=47440352
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210418058.9A Active CN102861034B (zh) | 2012-10-26 | 2012-10-26 | Gypensapogenin A在治疗或预防急性心衰的药物中的应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN102861034B (zh) |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN100450525C (zh) * | 2006-04-20 | 2009-01-14 | 朱国豪 | 一种治疗脑心血管疾病的中药组合物 |
WO2010002880A1 (en) * | 2008-06-30 | 2010-01-07 | Temple University-Of The Commonwealth System Of Higher Education | Topical steroidal formulations |
US8598339B2 (en) * | 2011-02-01 | 2013-12-03 | University Of Kansas | Withanolide isolated from Physalis longifolia and analogs and methods of use thereof |
-
2012
- 2012-10-26 CN CN201210418058.9A patent/CN102861034B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN102861034A (zh) | 2013-01-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103356669B (zh) | Houttuynoid A在制备治疗或预防急性心衰的药物中的应用 | |
CN103655549B (zh) | Myrtucommuacetalone在治疗或预防急性心衰药物中的应用 | |
CN102861034B (zh) | Gypensapogenin A在治疗或预防急性心衰的药物中的应用 | |
CN102885836B (zh) | Gypensapogenin B在制备治疗或预防急性心衰的药物中的应用 | |
CN103372007B (zh) | Chukrasone B在制备治疗或预防急性心衰的药物中的应用 | |
CN104098644A (zh) | 闭花木酮Cleistanone的O-(哌啶基)乙基衍生物、制备方法及其用途 | |
CN103393661A (zh) | Sarcaboside A在治疗或预防急性心衰的药物中的应用 | |
CN103356677B (zh) | Houttuynoid D在制备治疗或预防急性心衰的药物中的应用 | |
CN103356683B (zh) | Houttuynoid C在制备治疗或预防急性心衰的药物中的应用 | |
CN103356675B (zh) | Houttuynoid B在制备治疗或预防急性心衰的药物中的应用 | |
CN103385886B (zh) | Houttuynoid E在制备治疗或预防急性心衰的药物中的应用 | |
CN105497039A (zh) | Trigonoliimines C在制备治疗或预防急性心衰药物中的应用 | |
CN103751179B (zh) | 一种化合物在治疗或预防急性心衰药物中的应用 | |
CN103751176B (zh) | Trigoxyphin K在治疗或预防急性心衰药物中的应用 | |
CN103356529A (zh) | Sarcaboside B在制备治疗或预防急性心衰的药物中的应用 | |
CN103622964B (zh) | Trigolutesins A在治疗或预防急性心衰药物中的应用 | |
CN105168191A (zh) | 一种治疗或预防急性心衰药物及其应用 | |
CN103494824B (zh) | Kadcoccitones A在制备治疗或预防急性心衰药物中的应用 | |
CN103120670A (zh) | Eryngiolide A在治疗或预防急性心衰的药物中的应用 | |
CN105287503A (zh) | Foveolide A在治疗或预防急性心衰药物中的应用 | |
CN102988344A (zh) | Aphanamixoid A在制备治疗或预防急性心衰的药物中的应用 | |
CN103381166A (zh) | Chukrasone A在治疗或预防急性心衰的药物中的应用 | |
CN105287504A (zh) | Irciniastatin B在制备治疗或预防急性心衰药物中的应用 | |
CN103505456A (zh) | Racemosins A在制备治疗或预防急性心衰药物中的应用 | |
CN103285006A (zh) | Myriberine A在制备治疗或预防急性心衰药物中的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: RUDONG TECHNOLOGY CENTER Free format text: FORMER OWNER: NANJING UNIVERSITY Effective date: 20141225 |
|
C41 | Transfer of patent application or patent right or utility model | ||
COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 210093 NANJING, JIANGSU PROVINCE TO: 226400 NANTONG, JIANGSU PROVINCE |
|
TR01 | Transfer of patent right |
Effective date of registration: 20141225 Address after: 226400 No. 66 Youyi West Road, dug Town, Rudong County, Jiangsu, Nantong Patentee after: Rudong science and Technology Center Address before: 210093 Nanjing, Gulou District, Jiangsu, No. 22 Hankou Road Patentee before: Nanjing University |
|
TR01 | Transfer of patent right |
Effective date of registration: 20200424 Address after: No. 10, Fandi South Road, juegang Town, Rudong County, Nantong City, Jiangsu Province Patentee after: Rudong industrial and commercial information consulting service center Address before: 226400 No. 66 Youyi West Road, dug Town, Rudong County, Jiangsu, Nantong Patentee before: Rudong science and Technology Center |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20211227 Address after: Fengli town Xinjian West Road, Rudong County, Nantong City, Jiangsu Province 226400 Patentee after: Rudong Wenyuan investment and Development Co., Ltd Address before: 226400 No.10 Fandi South Road, juegang Town, Rudong County, Nantong City, Jiangsu Province Patentee before: Rudong industrial and commercial information consulting service center |
|
TR01 | Transfer of patent right |